Patients undergoing curative treatment for CRC
Conditions
Interventions
Patients are given a breath test during the first three years of follow-up if they come for a regular follow-up with imaging. If verification of only CEA determination (year 4 and 5) gives rise to ima
Sponsors
• The ‘Medisch Specialistisch Bedrijf’(MSB) of Isala has invested in The eNose Company, Zutphen, The Netherlands. The researchers have received a grant from the Innovation & Science fund Isala. • The eNose Company invests by making the eNose devices, disposable mouthpieces and analysis of the breath tests available.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Follow-up patients with an intentional curative treatment of CRC stage I to IV • a CRC treated with curative intent by means of a colorectal resection • curative treatment of synchronous metastases in combination with colorectal resection • curatively treated metachronous metastases, after colorectal resection 2. Age = 18 years.
Exclusion criteria
Exclusion criteria: 1. Not proficient in Dutch 2. Reason to believe that the patient cannot perform a breath test 3. CRC not treated curatively 4. CRC pT1N0Mx / pT1NxMx (patients receiving endoscopic control only) 5. Local (surgical or endoscopic) resection 6. Active treatment of other malignancies within the past three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the diagnostic accuracy of eNose in the detection of recurrent CRC | — |
Contacts
Public ContactIvonne Schoenaker
Isala
Outcome results
None listed